Published in final edited form as:

ACS Chem Biol. 2010 May 21; 5(5): 455–460. doi:10.1021/cb9002909.

Modulating the bioluminescence emission of photoproteins by in vivo site-directed incorporation of non-natural amino acids

Laura Rowe^{1,§}, Mark Ensor¹, Ryan Mehl², and Sylvia Daunert^{1,*}

¹ University of Kentucky, Department of Chemistry Rose Street, Lexington, Kentucky 40506

² Franklin and Marshall College, Department of Chemistry, 415 Harrisburg Avenue, Lancaster, Pennsylvania, 17603

Abstract

The in vivo incorporation of non-natural amino acids into specific sites within proteins has become an extremely powerful tool for bio- and protein chemists in recent years. One avenue that has yet to be explored however, is whether or not the incorporation of non-natural amino acids can tune the color of light emitted by bioluminescent proteins, whose light emission mechanisms are more complex and less well understood than their fluorescent counterparts. Bioluminescent proteins are becoming increasingly important in a variety of research fields, such as in situ imaging and the study of protein-protein interactions in vivo, and increased spectral variety of bioluminescent reporters is needed for further progress. Thus, herein we report the first successful spectral shifting (44 nm) of a bioluminescent protein, aequorin, via the site-specific incorporation of several non-natural amino acids into an integral amino acid position within the aequorin structure in vivo.

Light emitting proteins have become valuable and versatile tools in a plethora of biological and chemical applications. The visualization capabilities of these light-emitting proteins has rendered them invaluable as imaging reagents in a variety of *in vitro*, *in vivo*, and *in situ* studies, as well as being used as reporters in protein and cell assays, biosensors, environmental monitoring, biothreat assessment, and high-throughput screening of pharmaceuticals. Bioluminescent proteins in particular have received a significant amount of attention recently due to the advantages they possess over fluorescent proteins in terms of sensitivity of detection and for their use in longitudinal and circadian studies.(1) However, a current shortcoming of bioluminescent proteins lies in their limited spectral variety, and mutagenesis strategies aimed at rectifying this frequently cause partial or total loss of bioluminescent activity.(2) In an effort to circumvent this challenge we incorporated non-natural amino acids into an aromatic, H-bonding residue position (Y82) within the chromophore-binding site of the bioluminescent photoprotein aequorin and combined the non-natural aequorins with altered chromophore analogues. Our strategy involved expanding the repertoire of amino acids available for translation into aequorin by employing a site-specific *in vivo* non-natural amino acid incorporation method, which resulted not only in the successful site-specific incorporation of non-natural amino acids *in vivo* into a bioluminescent protein for the first time, but also in significant shifts of the bioluminescence emission maximum of aequorin. This study, therefore,

*Corresponding author: daunert@uky.edu.

§Current address: University of Cambridge, Department of Chemical Engineering and Biotechnology, Tennis Court Road, Cambridge, UK, CB2 1TN

Supporting Information Available: This material is available free of charge via the Internet. Supporting Information includes Tables 1-5 of mass spectral data, Table 6 showing specific activities of the proteins, Table 7 shows the bioluminescent half-life times of the proteins. Figure 1 of the SDS-PAGE of purified proteins, Figure 2 showing the structure of coelenterazines, and notes on mass spectral analysis.

presents a new method for rationally tuning bioluminescence color by producing new variants of aequorin using a format that will allow for the efficient 'scale-up' of these non-natural bioluminescent reporter proteins.

Aequorin is a globular, 22 kDa protein composed of four EF-hand binding domains. Aequorin contains a chromophore, coelenterazine, which is non-covalently bound to the interior hydrophobic core of the protein (Fig. 1). When calcium (or several other alkali metals) binds to the EF-hand loops on the outer domains of aequorin, a conformational change occurs that leads to the oxidation of the bound coelenterazine to an excited coelenteramide, which relaxes via the emission of a bioluminescent photon ($\lambda_{em} = 473 \text{ nm}$).⁽³⁾ Two general strategies have thus far been employed in altering the wavelength of emission of aequorin: site-directed natural mutagenesis and altering the structure of the coelenterazine chromophore.⁽⁴⁻⁶⁾ Previous work performed by us and others has shown that natural mutation of Tyr82 results in a shift of the emission maxima of aequorin while retaining high bioluminescence activity. Since the natural Y82 to F82 mutation shifts the emission maxima of aequorin by approximately 30 nm, we postulated that the introduction of different non-natural amino acids into the Y82 position would also result in large shifts in the emission wavelength..⁽⁷⁾

In order to site-specifically incorporate the non-natural amino acids into position 82 we utilized the amber codon, *in vivo* method using orthogonal tRNA and tRNA synthetases (see Methods).^(8,9) This non-natural amino acid incorporation method has been thoroughly developed and characterized by others and each of these synthetases have previously been shown to incorporate its specific non-natural amino acid into solely a TAG codon efficiently and quantitatively.⁽¹⁰⁾ We chose four non-natural phenylalanine derivatives for incorporation: 4-bromo-F, 4-iodo-F, 4-amino-F, and 4-methoxy-F (Fig. 1) due to their limited steric differences as compared to Tyr, and the altered electron donating and H-bonding capacity of the functional groups. In order to increase the diversity of bioluminescence properties, these four non-natural aequorin derivatives were also combined with coelenterazine analogues containing altered functionality at the C2 and C8 positions.(see Fig. 1). These have been previously shown to alter the emission maximum of aequorin while maintaining bioluminescence activity.^(4,5) Therefore, all four of the non-natural and natural aequorin derivatives were charged overnight with ten coelenterazine analogues and the emission maximum and bioluminescence half-life of each non-natural aequorin-coelenterazine analogue pair was obtained (see Table 1 and Table 7 in Supplementary Information).

Characterization of the newly prepared non-natural aequorin variants demonstrated that the incorporation of the non-natural amino acids resulted in a significant shift in the bioluminescence emission wavelength of aequorin. The maximal shift observed was when 4-methoxy-Phe was inserted at location 82 of aequorin (methoxy-82-Aeq). Specifically, methoxy-82-Aeq presented a 36 nm shift when paired with native coelenterazine, and an impressive 44 nm shift when coelenterazine *i* was incorporated (Fig. 2). The overall red shifts observed for the non-natural aequorin variants may be attributed to altering the H-bonding capacity and positioning of the protein with these mutations, since as previously mentioned the natural mutation from Tyr to Phe at position 82 yields a 20-30 nm red-shift in cysteine-free and wild-type aequorin.^(2,7) Furthermore, the data from Table 1 suggests that the incorporation of the non-natural amino acids 4-methoxy-F and 4-amino-F into aequorin affects all of the coelenterazine ligands in the same way, with the incorporation of 4-methoxy-F resulting in an approximately 35 nm bioluminescence red shift (31-37 nm) and 4-amino-F resulting in an approximately 12 nm bioluminescence red shift (10-14 nm) with all ten of the coelenterazine analogues. However, the incorporation of 4-bromo-F, and to a lesser extent 4-iodo-F, resulted in different shifts depending on the coelenterazine analogue that the non-natural aequorin was paired with. For example, Bromo82AEQ gave a 20 nm red-shift when paired with coelenterazine *native* and coelenterazine *i*, an 11-13 nm red-shift with coelenterazines *cp*, *f*,

and *fcp*, and merely a 4-8 nm red-shift with coelenterazines *h*, *hcp*, *ip*, and *n*. The non-natural amino acids 4-amino-F and 4-methoxy-F can both contribute to the stabilizing H-bonding network that is known from structural studies to occur between aequorin (Y82, W86, and H16) and the phenolic group (non-C2 phenol) of coelenterazine, whereas 4-bromo-F and 4-iodo-F cannot. It is perhaps this fundamental difference that causes the H-bonding capable non-natural amino acids to give the same degree of red-shift for every coelenterazine, whereas the degree of red-shift varies per coelenterazine in the non-natural amino acids incapable of H-bonding. The differences in red-shift amongst the coelenterazines in Bromo82AEQ and Iodo82AEQ are more difficult to explain, but it can be observed that, with the exception of coelenterazine *i*, the coelenterazines exhibiting larger red-shifts when paired with Bromo82AEQ (*ntv*, *f*, *fcp*, *cp*) all contain a group (phenol or F) in the C2 position which will allow H-bonding with the aequorin molecule, and the coelenterazines with smaller red-shifts (*h*, *ip*, *n*, *hcp*) do not have this H-bonding capacity. It is possible that steric, aromatic, and heavy atom interactions may also have an affect, yet it is quite likely that these H-bonding factors, in both the non-natural amino acid and the coelenterazine analogues, contribute largely to the observed trend differences in the non-natural aequorins.

While the exact mechanism of bioluminescence is still unconfirmed, changes in the wavelength of bioluminescence have been previously observed due to alteration in the extent of pi electron delocalization in the chromophore, as well as changes in the rigidity of the chromophore. The different H-bonding abilities of the natural and non-natural mutations could be altering the chromophore's electron delocalization or rigidity and therefore altering the wavelength of bioluminescence emission.(11,12) Another interesting trend when incorporating these non-natural amino acids into aequorin is the unique emission spectral shape of iodo-82-Aeq and bromo-82-Aeq when paired with the coelenterazine analogues containing altered C8 functionality (*cp*, *fcp*, *hcp*, *ip*). These non-natural aequorins exhibit either a large shoulder in the 420 nm range, or a broad and flat spectral shape whose maximum likely combines both the 470 nm and 420 nm spectral components equally (Fig. 2). This may be due to an unusually large population of the neutral coelenteramide species (420 nm) in addition to the anionic I coelenteramide species(470 nm).(13,14).

Additionally, the bioluminescent half-lives of the non-natural aequorin mutants shifted depending on the non-natural amino acid incorporated and the coelenterazine analogue utilized, with bioluminescent half-lives ranging from 0.12 s to 14.3 s (Table 7, Supplementary Information). The most significant half-life shifts occurred with the variation of the coelenterazine analogues (14 s), while, with the exception of coelenterazine *i*, the identity of the non-natural amino acid made far less difference in the bioluminescence half-life of these moieties (Table 7, Supplementary Information). The half-life shifts observed in these non-natural aequorins also corresponds well to the half-life trends previously observed when incorporating these coelenterazine analogues into natural aequorin mutants (4,5). Coelenterazine *i* in particular may exhibit it's exceptionally long half-life due to a heavy atom effect and may prove to be quite useful in imaging applications due to its extended bioluminescence emission. Lastly, we determined the specific activity of these non-natural aequorins(Supplementary Information), and found that although the bioluminescent intensities of our non-natural aequorins are lower than the native form, they are strong enough to be of utility in assay and cell based applications.

In the future we plan on incorporating additional non-natural amino acids into aequorin in order to further shift the emission maxima, as well as undertaking a more thorough characterization of these proteins. We also plan on incorporating non-natural amino acids containing groups such as benzophenones and ketones into aequorin in order to increase the utility of aequorin for *in vivo* applications such as protein-protein interaction studies. The long-term goal of this project is to use these non-natural bioluminescent proteins to track multiple cellular processes

simultaneously by taking advantage of the spectral and temporal resolution, and the photo-cross linking ability and unique chemical “handles” that site-specific incorporation of non-natural amino acids allows. The success in achieving significant emission shifts and spectral shape alterations in aequorin highlights the promise of non-natural amino acid incorporation in tuning the bioluminescence properties and diversity of not only other bioluminescent proteins, such as firefly and *Renilla* luciferase, but the properties of other reporter proteins as well.(15,16) We envision that the ability to rationally tailor and incorporate non-natural amino acids with unique functionalities into bioluminescent proteins in order to fine-tune their emission characteristics will create unique designer proteins with distinct characteristics. The plethora of unique functionalities that non-natural amino acids offer will greatly increase the breadth of applications to which the newly created bioluminescent reporter proteins are suited, including multimodal imaging and multiplexing technologies, spatial and temporal control of bioluminescent reporters *in vivo*, and bioluminescence resonance energy transfer (BRET) studies.(17-19)

Methods

Reagents

The Qwik-Change Site-Directed Mutagenesis Kit was purchased from Stratagene, oligonucleotide primers from Eurofins MWG Operon, the pBADHisA plasmid from Invitrogen, and restriction enzymes from either NEBiolabs or Promega. T4 DNA ligase and T4 DNA ligase buffer was purchased from Promega, exTaq DNA polymerase from Takara, plasmid DNA purification and gel extraction kits from Qiagen, and tris(hydroxymethyl)amino methane (Tris) free base, ethylenediaminetetraacetic acid (EDTA) sodium salt, glucose, sodium dodecyl sulfate (SDS), ampicillin, tetracycline, and arabinose were purchased from Sigma. All other components necessary for arabinose auto-induction media were obtained from Sigma or DIFCO. Glacial acetic acid was purchased from EM Science, all coelenterazines from Biotium, and all non-natural amino acids were from PepTech. SDS-PAGE precast gels were purchased from Invitrogen. Composition of different buffers used were as follows: Buffer A: 30 mM Tris-HCl containing 2 mM EDTA, pH 7.0; Buffer B: 30 mM Tris-HCl containing 2 mM EDTA, 1 mg/mL BSA, and 150 mM NaCl, pH 7.0; Buffer C: 30 mM Tris-HCl and 100 mM CaCl₂, pH 7.0. All chemicals were reagent grade or better and solutions were prepared using deionized (Milli-Q Water Purification System, Millipore) reverse osmosis purified water.

Apparatus

Protein was expressed by incubating bacteria in a Fisher Scientific orbital shaker incubator. Cell cultures were centrifuged in a Beckman J2-MI centrifuge. Purity of the protein was examined with Coomassie Blue staining with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a Novex Mini-cell apparatus from Invitrogen. Aequorin activity was measured using an Optocomp I luminometer from MGM Biomedical. The emission spectra of the aequorin-coelenterazine pairs were taken on a custom made SpectroScan instrument from ScienceWares, which is capable of obtaining spectra from flash reactions of luminescent samples that emit in the 400-700 nm range.

Mutation of aequorin and cloning into pBADHisA

The 82TAG aequorin mutant was prepared using the Qwik-Change Site Directed Mutagenesis Kit and the following primers: 5'-GGAAACTGATTGGCCTGCATAGATTGAAGGATGG-3' and 5'-CCATCCTTCAATCTATGCAGGCCAATCAGTTTCC-3'. This mutagenesis changed the codon for tyrosine (TAT) at position 82 in aequorin to a TAG stop codon. The template for the mutagenesis reaction was pIN4 containing the cysteine free aequorin. The mutant aequorin gene along with the ompA leader sequence from the pIN4 was amplified by PCR placing an

Nco I restriction site at the 5' end and a Hind III site at the 3' end. The sequence of the forward primer for this PCR was 5'-CCATGGGTATGAAAAAGACAGCTATCGCGATTGC-3'; while the reverse primer had the sequence 5'-AAGCTTAGGGGACAGCTCCACCGTAGAGCTTTTCGGAAGCAGGATCCATTGTGTAC-3'. The PCR was carried out using ExTaq polymerase with the following PCR parameters: 94 °C for 2 min, followed by 30 cycles of 94 °C × 30 s, 55 °C × 30 s, 72 °C × 60 s and ending with 72 °C for 7 min. The PCR product was inserted into the Nco I and Hind III sites of pBAD/HisA to produce pBADHisA-AEQ82TAG. Transformation of *E. coli* with this plasmid produced a system in which the expression of aequorin is regulated by the addition of arabinose to the culture medium. Expression of aequorin with the ompA leader sequence results in the protein being released into the culture medium.

Construction of the pDULE-pBADHisA-AEQ82TAG expression strains

Four pDULE vectors which allow for the site specific incorporation of four different non-natural amino acids were obtained from Dr. Peter Schultz (Scripps Research Institute) and Dr. Ryan Mehl (Franklyn and Marshall College).² Each of these pDULE plasmids coded for a tRNA and tRNA synthetase specific for the TAG codon and a single non-natural amino acid, either L-4-Aminophenylalanine, L-4-Bromophenylalanine, L-4-Iodophenylalanine, or L-4-Methoxyphenylalanine. These plasmids were transformed into chemically competent MAXEfficiency DH10B *E. coli* cells and transformants selected by plating on LB agar medium containing tetracycline (12 µg mL⁻¹). Following confirmation of the transformation via plasmid isolation, restriction enzyme digestion and DNA gel electrophoresis, the DH10B *E. coli* cells containing the pDULE plasmids were made chemically competent using the standard rubidium chloride method and transformed with pBADHisA-AEQ82TAG to produce four different strains, each specific for the incorporation one of the non-natural amino acids mentioned above. Selection for these transformants was by plating on LB agar medium containing both tetracycline (12 µg mL⁻¹) and ampicillin (100 µg mL⁻¹).

In vivo expression and purification of aequorin with non-natural amino acids site-specifically incorporated at position 82

Cells were grown in 500 mL of autoinduction medium consisting of M9 minimal salts medium containing 0.5 % glycerol, 0.048% glucose, 0.05% arabinose, 1 mM MgSO₄, 0.1 mM CaCl₂, leucine (80 µg mL⁻¹), 5 mL of 100× trace metals (see below), ampicillin (50 µg mL⁻¹), and tetracycline (6 µg mL⁻¹).

100× Trace Metals

boric acid	0.57 g
copper (II) sulfate pentahydrate	0.39 g
ferric chloride, 100g in 40 mL water	2.0 ml
manganese chloride tetrahydrate	4.0 g
sodium chloride	5.0 g
sodium molybdate dihydrate	0.5 g
magnesium sulfate heptahydrate	25.0 g
sulfuric acid	2.87 ml
zinc sulfate heptahydrate	1.0 g

The above were dissolved in 1 liter of H₂O and filtered through a 0.22 µm filter. The inoculum was prepared by growing cells overnight in 25 mL LB + ampicillin (50 µg mL⁻¹), tetracycline (6 µg mL⁻¹) at 37 °C × 250 rpm. The cells were pelleted and resuspended in 10 mL of the autoinduction medium and then added to 500 mL of autoinduction medium. Inoculated flasks were incubated at 37 °C × 250 rpm. When the optical density of the culture reached 0.2 to 0.4,

the non-natural amino acid was added to 1 mM final concentration. Depending on the solubility of the non-natural amino acid, the amino acid was first added to ~50 mL of autoinduction medium which was gently heated until the amino acid was dissolved. The dissolved non-natural amino acid was then filtered through a 0.22 μ m filter before adding to the culture. The culture was then allowed to grow at 37°C $\times$ 250 rpm overnight.

Purification of aequorin

The cells were pelleted at 12,000 g $\times$ 20 min and the supernatant was then transferred to a clean flask. The pH of the supernatant was adjusted to 4.3 by the slow drop wise addition of glacial acetic acid with stirring. The precipitated protein was then pelleted by centrifugation at 20,000 g $\times$ 20 min. The pellet was resuspended in 35 mL of 30 mM Tris/HCl, pH 7.5, 2 mM EDTA and the pH was adjusted to 7.5 by the drop wise addition of 1 N NaOH. The protein was recentrifuged at 20,000 $\times$ g for 20 minutes to remove particulates before purification. See Reference 4 for purification protocol.. Purified apoaequorin was then sterile filtered through a 0.2 μ m filter before storage at either 4 °C for short term storage or -20 °C for longer term storage.

Mass spectrometry

Proteins were run on SDS-PAGE and cut out of the stained gels. Gel pieces were digested with trypsin, and LC-ESI-MS-MS performed using a ThermoFinnigan LTQ. Resulting MS-MS spectra were searched against proteins in the Swiss-Prot database using the X!Tandem search engine.

Determination of aequorin activity

Aequorin activity was determined using an Optocomp I luminometer. Aequorin was diluted with 30 mM Tris/HCl, pH 7.5, 2 mM EDTA, 0.5% bovine serum albumin to ensure the amount of light produced was within the linear range of the instrument. Activity was triggered by injecting 50 μ L of 100 mM Tris/HCl, pH 7.5, 100 mM CaCl₂. Bioluminescence was counted at 0.1 s intervals for a total of 6 s.

Emission spectra of photoproteins

All emission spectra were produced using the SpectroScan luminometer from ScienceWares. The non-natural aequorins were first charged by incubating overnight at 4 °C with a five-fold molar excess of each of the different coelenterazines. Each charged non-natural aequorin was pipetted into a 96-well microtiter plate and scanned from 400-700 nm using the custom built CCD luminometer, following injection of 100 μ L of buffer C. For each well, the CCD took readings for 10 s, scanning an array of wavelengths from 400-700 nm, with an interval of 1.5 nm. All photoprotein spectra were measured in triplicate, blank corrected, and the mean of these three values were reported. A five to seven point moving average was also applied to select spectra in order to smooth the curves; this averaging did not alter the final emission maxima.

Half life determination of photoproteins

Non-natural aequorins were charged overnight with the appropriate coelenterazine analogue and then diluted with 100 mM Tris/HCl, pH 7.5 buffer until the maximum counts on the luminometer were between 5000 and 50,000 RLU's in order to not overload the PMT detector. A Polarstar 96 well microplate reading luminometer (BMG Labtech) was utilized with the bioluminescence signal of a 50 μ L sample was measured for 30 s following the injection of 100 μ L of triggering buffer (100 mM Tris-HCl, pH 7.5, 100 mM CaCl₂). All measurements were done in triplicate and blank subtracted. The mean bioluminescence decay spectra was fit with an exponential decay equation using GraphPad Prism 4.0 (GraphPad Software), and a

first order decay kinetics half life equation used to determine the bioluminescence half-life of each aequorin-coelenterazine pair.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

S.Daunert would like to thank the University of Kentucky for a University Research Professorship and a Gill Eminent Professorship. L.Rowe acknowledges funding from NSF-IGERT and NIH-Predocctoral Fellowships. This work was funded by a grant from the National Institutes of Health (GM 467917). The authors are grateful to P. Schultz from the Scripps Research Institute for his generous donation of pDULE and pBK plasmids

References

1. Hutchens M, Luker G. Cell Microbiol 2007;9(10):2315–2322. [PubMed: 17587328]
2. Dikici E, Qu X, Rowe L, Millner L, Logue C, Deo SK, Ensor CM, Daunert S. Protein Eng Des Sel 2009;22(4):243–248. [PubMed: 19168563]
3. Prendergast FG. Nature 2000;405(6784):291–293. [PubMed: 10830945]
4. Rowe L, Dikici E, Logue C, Deo SK, Ensor CM, Daunert S. Protein Eng Des Sel 2009;21(1):73–81. [PubMed: 18175778]
5. Shimomura O, Musicki B, Kishi Y. Biochem J 1988;251(2):405–410. [PubMed: 3401214]
6. Vysotski ES, Lee J. Acc Chem Res 2004;37:405–415. [PubMed: 15196050]
7. Stepanyuk GA, Golz S, Markova SV, Frank LA, Lee J, Vysotski ES. FEBS Letters 2005;579:1008–1014. [PubMed: 15710383]
8. Wang L, Brock A, Herberich B, Schultz PG. Science 2001;291(5516):498–500. [PubMed: 11313494]
9. Farrell IS, Toroney R, Hazen JL, Chin JW, Mehl RA. Nature Methods 2005;2(5):377–384. [PubMed: 16170867]
10. Jackson JC, Duffy SP, Hess KR, Mehl RA. JACS 2006;128(34):11124–7.
11. Branchini B, Southworth TL, Murtiashaw MH, Magyar RA, Gonzalez SA, Ruggiero MC, Stroh JG. Biochem 2004;43:7255–7262. [PubMed: 15182171]
12. Nakatsu T, Ichiyama S, Hiratake J, Saldhna A, Kobashi N, Sakata K, Kato H. Nature 2006;440:372–376. [PubMed: 16541080]
13. Belogurova NV, Kudryasheva NS, Alieva RR, Sizykh AG. J Photochem Photobiol B 2008;92(2):117–122. [PubMed: 18602272]
14. Vysotski ES, et al. Biochemistry 2003;42:6013–6024. [PubMed: 12755603]
15. Viviani VR. Cell Mol Life Sci 2002;59:1833–1850. [PubMed: 12530517]
16. Ohmiya Y. Japanese Journal of Applied Physics 2005;44(9A):6368–6379.
17. Xie J, Schultz PG. Curr Opin Chem Biol 2005;9(6):548–554. [PubMed: 16260173]
18. Kim SB, Otani Y, Umezawa H, Tao H. Anal Chem 2007;79(13):4820–4826. [PubMed: 17539598]
19. Prinz A, Reither G, Diskar M, Schultz C. Proteomics 2008;8:1179–1196. [PubMed: 18283669]

Figure 1.

A. The X-ray crystal structure of aequorin with the tyrosine at position 82 highlighted in red CPK and the coelenterazine chromophore in ball and stick representation. **B.** The coelenterazine analogues utilized had altered functionality at positions C2 and C8. **C.** The structures of the non-natural amino acids incorporated: the R group of the native Tyr residue (1.), 4-methoxy-Phe (2.), 4-iodo-Phe (3.), 4-bromo-Phe (4.), 4-amino-Phe (5.). **D.** The structures of the C2 and C8 groups for the different coelenterazine analogues.

Figure 2.

A. Spectral differences of natural versus non-natural aequorin bioluminescence (green = cysteine free aequorin + coelenterazine *cp*, blue = cysteine-free aequorin + coelenterazine *native*, red = methoxy-82-aequorin + coelenterazine *i*). **B.** Altered spectral shape of bromo-82-aequorin (green = bromo-82-aequorin + coelenterazine *cp*, red = bromo-82-aequorin + coelenterazine *native*, blue = cysteine-free aequorin + coelenterazine *native*).

Table 1

Emission maxima (nm) of aequorin with non-natural amino acids with coelenterazine analogues. Aeq Cys-free is the baseline mutant used, in which all 3 native Cys residues have been mutated to Ser. Amino82AEQ is aequorin with 4-amino-Phe substituted for Tyr at position 82, Bromo82AEQ is aequorin with 4-bromo-Phe substituted for Tyr at position 82, etc.

Coelenterazine	Aequorin-cys free	Amino82AEQ	Bromo82AEQ	Iodo82AEQ	Methoxy82AEQ
native	472	483	491	487	509
i	484	496	504	493	517
cp	454	466	465	470	489
f	480	492	493	490	515
fcp	463	477	475	476	498
h	472	484	480	482	509
hcp	454	466	458	465	488
ip	454	465	461	465	485
n	475	485	481	485	511